ATE178484T1 - Protein enthaltende stabilisierte formulierung und dosierungskit - Google Patents

Protein enthaltende stabilisierte formulierung und dosierungskit

Info

Publication number: ATE178484T1
Authority: AT; Austria
Prior art keywords: protein containing; stabilized formulation; containing stabilized; dosage kit; kit
Prior art date: 1994-05-04

Application number

AT95401012T

Other languages

English (en)

Inventor

Alain Bayol

Thierry Breul

Patrice Dupin

Philippe Faure

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-04

Filing date

1995-05-02

Publication date

1999-04-15

1995-05-02 Application filed by Sanofi Sa filed Critical Sanofi Sa

1999-04-15 Application granted granted Critical

1999-04-15 Publication of ATE178484T1 publication Critical patent/ATE178484T1/de

Links

102000004169 proteins and genes Human genes 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
229930195725 Mannitol Natural products 0.000 abstract 2
235000004279 alanine Nutrition 0.000 abstract 2
235000010355 mannitol Nutrition 0.000 abstract 2
239000000594 mannitol Substances 0.000 abstract 2
235000018102 proteins Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Enzymes And Modification Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT95401012T 1994-05-04 1995-05-02 Protein enthaltende stabilisierte formulierung und dosierungskit ATE178484T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9405486A FR2719479B1 (fr)	1994-05-04	1994-05-04	Formulation stable lyophilisée comprenant une protéine: kit de dosage.

Publications (1)

Publication Number	Publication Date
ATE178484T1 true ATE178484T1 (de)	1999-04-15

Family

ID=9462880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95401012T ATE178484T1 (de)	1994-05-04	1995-05-02	Protein enthaltende stabilisierte formulierung und dosierungskit

Country Status (25)

Country	Link
US (1)	US5763409A (de)
EP (1)	EP0682944B1 (de)
JP (1)	JP2948125B2 (de)
KR (1)	KR100273053B1 (de)
CN (1)	CN1088583C (de)
AT (1)	ATE178484T1 (de)
AU (1)	AU694763B2 (de)
CA (1)	CA2148537C (de)
CZ (1)	CZ286195B6 (de)
DE (1)	DE69508837T2 (de)
DK (1)	DK0682944T3 (de)
ES (1)	ES2131781T3 (de)
FI (1)	FI117321B (de)
FR (1)	FR2719479B1 (de)
GR (1)	GR3030146T3 (de)
HU (1)	HU220220B (de)
IL (1)	IL113578A (de)
MX (1)	MX9502034A (de)
NO (1)	NO320364B1 (de)
NZ (1)	NZ272045A (de)
PL (1)	PL179240B1 (de)
RU (1)	RU2136306C1 (de)
SI (1)	SI0682944T1 (de)
TW (1)	TW397687B (de)
ZA (1)	ZA953596B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2226575C (en) *	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
US6685940B2 (en) *	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
ZA966075B (en) *	1995-07-27	1998-01-19	Genentech Inc	Protein formulation.
DE19539574A1 (de) *	1995-10-25	1997-04-30	Boehringer Mannheim Gmbh	Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
FR2740686B1 (fr)	1995-11-03	1998-01-16	Sanofi Sa	Formulation pharmaceutique lyophilisee stable
EP0852951A1 (de) *	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
FR2768341B1 (fr) *	1997-09-18	2000-04-14	Lab Francais Du Fractionnement	Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
EP0913178A1 (de) *	1997-11-03	1999-05-06	Boehringer Mannheim Gmbh	Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialen mittels Konvektionstrocknung und die erhaltenen Produkte
EP0913177A1 (de)	1997-11-03	1999-05-06	Roche Diagnostics GmbH	Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
WO1999047174A1 (en) *	1998-03-18	1999-09-23	Cambridge Biostability Limited	Amorphous glasses for stabilising sensitive products
EP1820516B1 (de) *	1999-02-22	2013-07-24	University of Connecticut	Neue albuminfreie Faktor VIII Formulierungen
AU1316201A (en) *	1999-10-28	2001-05-08	Institut Neftekhimicheskogo Sinteza Imeni A.V.T.O. Pchieva Rossiiskoi Akademii Nauk (Inkhsran)	Polypeptide composition
US6653062B1 (en)	2000-07-26	2003-11-25	Wisconsin Alumni Research Foundation	Preservation and storage medium for biological materials
PT1343518E (pt)	2000-11-07	2009-08-03	Novartis Vaccines & Diagnostic	Composições de interferão estabilizadas
US6887462B2 (en) *	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
JP2005508220A (ja) *	2001-10-24	2005-03-31	パーリ・ゲーエムベーハー	薬用組成物調製用具
CN102353569A (zh)	2002-05-13	2012-02-15	贝克顿·迪金森公司	蛋白酶抑制剂样品采集系统
US6803046B2 (en) *	2002-08-16	2004-10-12	Bracco International B.V.	Sincalide formulations
PT1589949E (pt) *	2003-01-08	2008-11-06	Novartis Vaccines & Diagnostic	Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares
GB0304636D0 (en) *	2003-02-28	2003-04-02	Britannia Pharmaceuticals Ltd	Pharmaceutical composition for nasal delivery
PT1610820E (pt) *	2003-04-04	2010-12-16	Novartis Ag	Formulações de elevada concentração de anticorpos e proteínas
DE10333317A1 (de) *	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB0404586D0 (en) *	2004-03-01	2004-04-07	Britannia Pharmaceuticals Ltd	Improvements in or relating to organic materials
US11229746B2 (en)	2006-06-22	2022-01-25	Excelsior Medical Corporation	Antiseptic cap
CN101808657A (zh) *	2006-11-07	2010-08-18	赛诺菲巴斯德生物制剂公司	冻干法稳定疫苗
AU2008269086B2 (en) *	2007-06-25	2014-06-12	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) *	2007-08-06	2007-09-12	Britannia Pharmaceuticals Ltd	Improvements in or relating to powdered medicaments for nasal delivery
US9078992B2 (en)	2008-10-27	2015-07-14	Pursuit Vascular, Inc.	Medical device for applying antimicrobial to proximal end of catheter
EP2385825B1 (de)	2008-11-07	2018-10-10	University of Connecticut	Faktor-viii-formulierungen
MX2011005672A (es) *	2008-11-28	2011-06-20	Abbott Lab	Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
CN102655876B (zh) *	2009-11-03	2015-07-15	基立福疗法公司	α-1蛋白酶抑制剂组合物、方法和试剂盒
SG181628A1 (en) *	2009-12-22	2012-07-30	Celldex Therapeutics Inc	Vaccine compositions
RU2448156C1 (ru) *	2011-03-17	2012-04-20	Эспосито Трейдинг Лтд	Способ получения лиофилизированной субстанции
RU2448158C1 (ru) *	2011-03-24	2012-04-20	Эспосито Трейдинг Лтд	Способ получения препарата фортелизин, обладающего фибринолитическими свойствами, и его применение для лечения инфаркта миокарда
US10166381B2 (en)	2011-05-23	2019-01-01	Excelsior Medical Corporation	Antiseptic cap
CA2841832C (en)	2011-07-12	2019-06-04	Icu Medical, Inc.	Device for delivery of antimicrobial agent into a trans-dermal catheter
CA2856382C (en) *	2011-11-22	2020-07-14	Siemens Healthcare Diagnostics Inc.	Devices containing dried reagents for reconstitution as calibration and/or quality control solutions, and methods of production and use thereof
US20140017318A1 (en) *	2012-07-10	2014-01-16	Kevin O'Connell	Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en)	2012-08-21	2016-04-19	Intervet Inc.	Liquid stable virus vaccines
US9480739B2 (en)	2013-03-15	2016-11-01	Intervet Inc.	Bovine virus vaccines that are liquid stable
US9393298B2 (en)	2013-03-15	2016-07-19	Intervet Inc.	Liquid stable bovine virus vaccines
AR097762A1 (es)	2013-09-27	2016-04-13	Intervet Int Bv	Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105848645A (zh)	2013-09-27	2016-08-10	韩美药品株式会社	持续型人生长激素制剂
AR099470A1 (es)	2014-02-17	2016-07-27	Intervet Int Bv	Vacunas de virus de aves de corral líquidas
TWI670085B (zh)	2014-02-19	2019-09-01	荷蘭商英特威國際公司	液體穩定之豬病毒疫苗
AU2015252808B2 (en)	2014-05-02	2019-02-21	Excelsior Medical Corporation	Strip package for antiseptic cap
AU2016262400B2 (en)	2015-05-08	2021-01-21	Icu Medical, Inc.	Medical connectors configured to receive emitters of therapeutic agents
AU2016274868B2 (en)	2015-06-11	2021-02-18	Attwill Medical Solutions Inc.	Medical devices, systems, and methods utilizing antithrombin-heparin compositions
CA3040277C (en)	2016-10-14	2025-08-12	Icu Medical, Inc.	DISINFECTANT CAPS FOR MEDICAL FITTINGS
WO2018204206A2 (en)	2017-05-01	2018-11-08	Icu Medical, Inc.	Medical fluid connectors and methods for providing additives in medical fluid lines
US11110063B2 (en)	2017-08-25	2021-09-07	MAIA Pharmaceuticals, Inc.	Storage stable sincalide formulations
EP3765123B1 (de)	2018-03-16	2026-07-15	ICU Medical, Inc.	Desinfektionskappen für medizinische konnektoren
US11517732B2 (en)	2018-11-07	2022-12-06	Icu Medical, Inc.	Syringe with antimicrobial properties
US11534595B2 (en)	2018-11-07	2022-12-27	Icu Medical, Inc.	Device for delivering an antimicrobial composition into an infusion device
US11400195B2 (en)	2018-11-07	2022-08-02	Icu Medical, Inc.	Peritoneal dialysis transfer set with antimicrobial properties
US11541221B2 (en)	2018-11-07	2023-01-03	Icu Medical, Inc.	Tubing set with antimicrobial properties
US11541220B2 (en)	2018-11-07	2023-01-03	Icu Medical, Inc.	Needleless connector with antimicrobial properties
EP3883638A1 (de)	2018-11-21	2021-09-29	ICU Medical, Inc.	Antimikrobielle vorrichtung mit einer kappe mit ring und einsatz
JP7888563B2 (ja)	2020-12-07	2026-07-13	アイシーユー・メディカル・インコーポレーテッド	医療用コネクタのためのキャップシステム、キャップと共に使用されるベース要素、及びベース要素上にキャップを保持するための方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5822445B2 (ja) *	1982-07-08	1983-05-09	株式会社ミドリ十字	安定な固体の人血漿コリンエステラ−ゼ製剤の製法
JPS6197229A (ja) *	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
US5037644A (en) *	1986-10-27	1991-08-06	Cetus Corporation	Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
US5266310A (en) *	1987-09-17	1993-11-30	Boehringer Ingelheim International Gmbh	Stabilization of therapeutically active proteins in pharmaceutical preparations
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
JPH0296536A (ja) *	1988-09-29	1990-04-09	Green Cross Corp:The	プラスミノゲン乾燥製剤
EP0396777A4 (en) *	1988-11-14	1991-03-13	Otsuka Pharmaceutical Co., Ltd.	Interferon preparation for nasal administration
DE59007142D1 (de) *	1990-01-18	1994-10-20	Cereria Amos Sgarbi Spa	Grablicht.
US5192743A (en) *	1992-01-16	1993-03-09	Genentech, Inc.	Reconstitutable lyophilized protein formulation
SE9201073D0 (sv) *	1992-04-03	1992-04-03	Kabi Pharmacia Ab	Protein formulation
DE4239877C1 (de) *	1992-11-27	1994-03-17	Boehringer Ingelheim Int	Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung

1994
- 1994-05-04 FR FR9405486A patent/FR2719479B1/fr not_active Expired - Lifetime
1995
- 1995-04-26 CZ CZ19951081A patent/CZ286195B6/cs not_active IP Right Cessation
- 1995-04-28 JP JP7106227A patent/JP2948125B2/ja not_active Expired - Lifetime
- 1995-04-28 PL PL95308416A patent/PL179240B1/pl unknown
- 1995-05-02 MX MX9502034A patent/MX9502034A/es unknown
- 1995-05-02 AT AT95401012T patent/ATE178484T1/de active
- 1995-05-02 NZ NZ272045A patent/NZ272045A/en not_active IP Right Cessation
- 1995-05-02 AU AU17774/95A patent/AU694763B2/en not_active Expired
- 1995-05-02 ES ES95401012T patent/ES2131781T3/es not_active Expired - Lifetime
- 1995-05-02 DE DE69508837T patent/DE69508837T2/de not_active Expired - Lifetime
- 1995-05-02 DK DK95401012T patent/DK0682944T3/da active
- 1995-05-02 US US08/432,839 patent/US5763409A/en not_active Expired - Lifetime
- 1995-05-02 SI SI9530241T patent/SI0682944T1/xx unknown
- 1995-05-02 EP EP95401012A patent/EP0682944B1/de not_active Expired - Lifetime
- 1995-05-02 IL IL11357895A patent/IL113578A/xx not_active IP Right Cessation
- 1995-05-03 CA CA002148537A patent/CA2148537C/en not_active Expired - Lifetime
- 1995-05-03 HU HU9501276A patent/HU220220B/hu unknown
- 1995-05-03 FI FI952119A patent/FI117321B/fi not_active IP Right Cessation
- 1995-05-03 RU RU95107153/14A patent/RU2136306C1/ru active
- 1995-05-03 NO NO19951724A patent/NO320364B1/no not_active IP Right Cessation
- 1995-05-03 TW TW084104433A patent/TW397687B/zh not_active IP Right Cessation
- 1995-05-04 CN CN95104797A patent/CN1088583C/zh not_active Expired - Lifetime
- 1995-05-04 KR KR1019950011157A patent/KR100273053B1/ko not_active Expired - Lifetime
- 1995-05-04 ZA ZA953596A patent/ZA953596B/xx unknown
1999
- 1999-05-06 GR GR990401232T patent/GR3030146T3/el unknown

Also Published As

Publication number	Publication date
NO320364B1 (no)	2005-11-28
DE69508837T2 (de)	1999-11-04
AU694763B2 (en)	1998-07-30
NO951724L (no)	1995-11-06
IL113578A (en)	1999-10-28
RU2136306C1 (ru)	1999-09-10
HU9501276D0 (en)	1995-06-28
PL308416A1 (en)	1995-11-13
HU220220B (hu)	2001-11-28
CN1116522A (zh)	1996-02-14
FR2719479B1 (fr)	1996-07-26
HUT72325A (en)	1996-04-29
FI952119L (fi)	1995-11-05
SI0682944T1 (en)	1999-08-31
FR2719479A1 (fr)	1995-11-10
ES2131781T3 (es)	1999-08-01
TW397687B (en)	2000-07-11
NZ272045A (en)	1996-02-27
AU1777495A (en)	1995-11-16
KR950031103A (ko)	1995-12-18
CZ108195A3 (en)	1996-02-14
MX9502034A (es)	1997-02-28
KR100273053B1 (ko)	2000-12-01
EP0682944A1 (de)	1995-11-22
EP0682944B1 (de)	1999-04-07
DK0682944T3 (da)	1999-10-18
IL113578A0 (en)	1995-08-31
DE69508837D1 (de)	1999-05-12
US5763409A (en)	1998-06-09
NO951724D0 (no)	1995-05-03
FI952119A0 (fi)	1995-05-03
CZ286195B6 (cs)	2000-02-16
JPH0853361A (ja)	1996-02-27
GR3030146T3 (en)	1999-08-31
CA2148537A1 (en)	1995-11-05
JP2948125B2 (ja)	1999-09-13
CA2148537C (en)	2002-07-16
ZA953596B (en)	1996-11-04
CN1088583C (zh)	2002-08-07
PL179240B1 (pl)	2000-08-31
FI117321B (fi)	2006-09-15

Publication	Publication Date	Title
DE69508837D1 (de)	1999-05-12	Protein enthaltende stabilisierte Formulierung und Dosierungskit
HRP20000181B1 (en)	2006-07-31	2-methyl-thieno-benzodiazepine formulation
IT1227154B (it)	1991-03-19	Composizioni farmaceutiche per uso ginecologico a base di lattobacilli
SE8903042L (sv)	1990-05-11	Pharmaceutical compositions comprising cyklosporins
DE68924540D1 (de)	1995-11-16	Medizinische Aerosolformulierungen.
ATA27290A (de)	1998-05-15	Neue cyclosporin enthaltende galenische formulierungen
NO985981D0 (no)	1998-12-18	Insulinpreparater som inneholder NaCl
NO921256D0 (no)	1992-03-31	Aminosyre-beta-lyaseenzyminhibitor som deodoranter
SV1998000040A (es)	1999-03-16	Composiciones farmaceuticas ref. pu3210/sv
DE69009795D1 (de)	1994-07-21	Muramylpeptid-Derivate und diese enthaltende immunregulierende Zusammensetzungen.
ITMI911604A1 (it)	1992-12-11	Procedimento per la preparazione della n- (2, 6-diclorofenil) -n-fenil-n-(cloroacetil)-ammina.
DK0626173T3 (da)	1997-05-12	Aerosolpræparat indeholdende fusafungin
ATE80143T1 (de)	1992-09-15	Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.
ATE119940T1 (de)	1995-04-15	Gewebs-plasminogen-aktivator-derivat.
RU96106995A (ru)	1998-07-27	Свечи с лидазой
DE69002027D1 (de)	1993-07-29	(3-diethylaminopropyl)-1-amino-5-methyldipyrido(4,3-b)(3,4-f)indoltrihydrochlorid.
ATE62593T1 (de)	1991-05-15	Physiologisch wirksame und naehrende zusammensetzung.
IT1230571B (it)	1991-10-28	Procedimento per la preparazione di formulazioni antiacido ad azione protratta e formulazioni cosi'ottenute.
IT215496Z2 (it)	1990-09-11	Gioco di pazienza ed abilita'.
ATE82855T1 (de)	1992-12-15	2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
IT8620976A0 (it)	1986-06-30	Composizione farmaceutica a base di n-acil-fosfatidiletanolammina, procedimento per la preparazione della stessa, specialita'farmaceutica e uso della stessa.